PRODUCT MONOGRAPH

Pr FLAREX®
Fluorometholone Acetate Ophthalmic Suspension
0.1% w/v
Corticosteroid

Alcon Canada Inc
2665 Meadowpine Blvd
Mississauga, Ontario
L5N 8C7
www.alcon.ca

Date of Preparation: June 2, 1987
Date of Revision: December 15, 2015
Submission Control No.: 187707

*a trademark of Novartis
© 1987, 2015 Novartis
PRODUCT MONOGRAPH

Fluorometholone Acetate Ophthalmic Suspension

ACTION

Corticosteroids suppress the inflammatory response (edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, deposition of collagen and scar formation), to chemical, immunological, or mechanical irritants. Corticosteroids may cause a rise in intraocular pressure in susceptible individuals. They are absorbed into aqueous humour, cornea, iris, choroid, ciliary body and retina. Systemic absorption occurs but may be significant only at higher doses than recommended.

INDICATIONS

FLAREX® (Fluorometholone Acetate Ophthalmic Suspension) is indicated for the treatment of allergic and other steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the eye.

CONTRAINDICATIONS

FLAREX® is contraindicated in patients with:
- Hypersensitivity to fluorometholone or any component of this preparation (for a complete listing, see PHARMACEUTICAL INFORMATION).
- Hypersensitivity to other corticosteroids.
- Acute superficial herpes simplex keratitis, vaccinia, varicella, and most viral diseases of cornea and conjunctiva.
- Mycobacterial infections, including tuberculosis of the eye.
- Fungal diseases of the eye.
- Acute untreated infections of the eye which, like other diseases caused by microorganisms, may be masked or enhanced by the presence of the steroid.

WARNINGS AND PRECAUTIONS

Not for injection.

The initial prescription and renewal of FLAREX® should be made only after appropriate ophthalmologic examination (including but not limited to intraocular pressure assessment and slit lamp biomicroscopy). If signs and symptoms fail to improve after two days, the patient should be re-evaluated. FLAREX® should not be used beyond 10 days, unless absolutely necessary, and only under ophthalmologic monitoring.
Use of topical corticosteroid may cause increased intraocular pressure (IOP). It is necessary that the IOP be checked frequently, particularly in patients with a history or family history of glaucoma. Prolonged use may result in glaucoma, damage to the optic nerve, defects in visual acuity and visual field, and/or posterior subcapsular cataract formation.

The risk of corticosteroid-induced raised IOP and/or cataract formation is increased in predisposed patients (e.g. diabetes).

Acute infections of the eye may be masked or exacerbated by the presence of steroid medications. Prolonged use may increase the risk of secondary ocular infections from pathogens due to suppression of the host response.

Topical ophthalmic corticosteroids may slow corneal wound healing. In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with the chronic use of topical steroids. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are also known to slow or delay healing; therefore, concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application; fungus invasion must be considered in any persistent corneal ulceration where a steroid has been or is in use. FLAREX® therapy should be discontinued if fungal infection occurs.

In diseases due to microorganisms, the infection may be masked, enhanced or activated by corticosteroids. Whenever there is a possibility of infection, supplemental therapy with suitable antibiotic agents should be considered.

Patients should be advised to inform their physicians of any prior use of corticosteroids. If sensitivity or other untoward reactions occur, the patient should be advised to discontinue the medication.

The wearing of contact lenses is discouraged during treatment of an ocular inflammation. FLAREX® contains benzalkonium chloride, which may cause irritation and is known to discolor soft contact lenses. FLAREX® should not be used while the patient is wearing soft contact lenses. Avoid contact with soft contact lenses. In case patients are allowed to wear contact lenses, they must be instructed to remove contact lenses prior to application of FLAREX® and wait at least 15 minutes before re-insertion.

Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery.

**Pregnancy:**

FLAREX® should not be used during pregnancy unless the potential benefits to the mother clearly outweigh the risks to the fetus. The safety of FLAREX® in pregnant women has not been established. However, fluorometholone has been shown to be embryocidal, fetotoxic, and teratogenic in rabbits when administered by ocular instillation (see **TOXICOLOGY**).
Nursing Women:
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when FLAREX® is administered to a nursing woman.

Pediatric Use (< 18 years of age):
Safety and effectiveness of FLAREX® in children have not been established.

ADVERSE REACTIONS
Glaucoma with optic nerve damage, visual acuity and field defects, cataract formation, and secondary ocular infection following suppression of host response may occur. Extended ophthalmic use of corticosteroid drugs may cause increased intraocular pressure in certain individuals and in those diseases causing thinning of the cornea, perforation has been known to occur. Rarely, filtering blebs have been reported when topical steroids have been used following cataract surgery. Occasionally stinging or burning may occur.

Post-Market Adverse Drug Reactions
Eye disorders: Intraocular pressure increased, eye pain, eye irritation, ocular discomfort, foreign body sensation in eyes, vision blurred, ocular hyperaemia, lacrimation increased
Others: Dysgeusia

SYMPTOMS AND TREATMENT OF OVERDOSE
Overdosage in the use of topical ophthalmic corticosteroids is a remote possibility. Discontinue medication when heavy or protracted use is suspected.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

DOSAGE AND ADMINISTRATION
One to two drops instilled into the conjunctival sac of the affected eye(s) two to four times daily. During the initial 24 to 48 hours, the dosage may be safely increased to two drops every two hours. Care should be taken not to discontinue therapy prematurely.

If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.

Special Instructions:
Patients should be instructed to shake well before using and to avoid contamination of the dropper tip.
AVAILABILITY

FLAREX® is available as a sterile ophthalmic suspension of fluorometholone acetate 0.1% in DROP-TAINER® dispensers of 5 mL. The suspension is preserved with benzalkonium chloride 0.01%.

Stability and Storage Recommendations:
Protect from freezing and store upright at room temperature. Keep out of the reach and sight of children.

PHARMACEUTICAL INFORMATION

Drug Substance:
Proper Name: Fluorometholone acetate
Chemical Name: 9-fluoro-11β,17-dihydroxy-6α-methylpregna-1,4-diene-3,20-dione, 17-acetate.

Structural Formula:

![Structural formula of Fluorometholone acetate](image)

Molecular Formula: \( C_{24}H_{31}FO_5 \)
Molecular Weight: 418.5
Description: White to creamy white powder.
Solubility: Freely soluble in chloroform and acetone, soluble in ethanol very slightly soluble in water.
Melting Point: approximately 230°C
Specific Rotation: + 28° in chloroform.

Composition:
FLAREX® is a sterile, suspension of fluorometholone acetate 0.1% w/v with benzalkonium chloride 0.01% w/v (as preservative), sodium chloride, monobasic sodium phosphate, edetate disodium, hydroxyethyl cellulose, tyloxapol, sodium hydroxide and/or hydrochloric acid (to adjust pH) and purified water.
PHARMACOLOGY

Animal Studies:
Past experience demonstrates that one may alter, by derivatization, the bioavailability and consequently, the potency and efficacy of topical ocular steroids. It is known that ocular tissues contain enzymes capable of hydrolysing esters, especially acetate esters of steroids. The acetate group may confer a change in the lipophilicity of the steroid which in turn may alter its rate of passage through the cornea. It is believed that the acetate group is removed from the molecule through hydrolysis by the ocular enzymes.

To determine whether or not the 17-acetate ester of fluorometholone retains adequate anti-inflammatory activity in the eye, its efficacy in comparison to other steroids was studied using an immunogenic uveitis model in albino rabbits. Fluorometholone acetate exhibited anti-inflammatory efficacy in each of six uveitis experiments. In this series of experiments, fluorometholone acetate and fluorometholone alcohol (both at 0.1%) were equally potent anti-inflammatory agents. As these studies were not designed to give a complete dose response comparison, it cannot be concluded that the two compounds are precisely equivalent.

The effect of 0.1% Fluorometholone Acetate Ophthalmic Suspension has been studied in the rabbit using a keratitis model in which the invasion of the cornea by polymorphonuclear leukocytes was measured. Hourly topical administration of the drug suspension produced an average reduction of 46.8% in the polymorphonuclear leukocytes invading the corneal stroma. According to a similar experimental protocol, 0.1% Fluorometholone Alcohol Ophthalmic Suspension was shown to produce a mean decrease of 30.8% in corneal inflammatory activity as measured by leukocyte invasion. Thus, in the cornea, fluorometholone acetate appears to have a greater efficacy, as compared to fluorometholone alcohol, for reducing the number of leukocytes invading that tissue following an inflammatory stimulus.

Clinical Studies:
The efficacy of corticosteroids for the treatment of inflammatory conditions in the eye is well established. Various steroids such as dexamethasone alcohol or phosphate, prednisolone acetate or phosphate, and fluorometholone alcohol are marketed for this purpose. The anti-inflammatory effects of the steroids reduce the severity of the signs and symptoms of ocular inflammation and may avert permanent structural changes which can affect the vision.

The intrinsic anti-inflammatory activity of the corticosteroid and its ability to penetrate the cornea, which is the primary route of absorption of topically applied drugs into the aqueous humor, determine not only its efficacy but also the propensity of the compound to provoke side effects. Some physicochemical properties of the steroid esters may vary from those of the parent alcohols. Properties such as solubility and partitioning between aqueous and nonaqueous solvents may affect the bioavailability of molecules in the eye.

Double masked randomized studies have shown that FLAREX® was significantly (p = 0.03) more effective than Fluorometholone Alcohol and equally effective as Prednisolone Acetate in the treatment of external ocular inflammation of non-microbial origin. All three steroids were essentially equally effective in the treatment of anterior uveal inflammation.
The elevation of intraocular pressure (IOP) with prolonged use is perhaps the most serious effect of topical ophthalmic use of corticosteroids. The liability of provoking this effect varies among the currently marketed drugs, with the available evidence indicating that fluorometholone alcohol has less propensity to raise IOP in susceptible individuals compared to other steroids such as dexamethasone, prednisolone and their derivatives.

Fluorometholone acetate is the 17-acetate ester of fluorometholone. It is probable that this compound is hydrolysed in vivo to regenerate fluorometholone alcohol. Thus, fluorometholone acetate should share the same low propensity for raising IOP as fluorometholone.

In healthy volunteers, dosed with two drops of FLAREX® four times per day for 15 days, the IOP was elevated in only 3 of the 20 individuals. In a double masked crossover study with Dexamethasone Phosphate 0.1%, FLAREX® demonstrated a significantly lower propensity to raise IOP.

**TOXICOLOGY**

Fluorometholone Ophthalmic Suspension 0.1% has been marketed over the last decade in the United States, Canada and other countries as an ophthalmic corticosteroid. Animal toxicity studies of fluorometholone, including acute intraperitoneal LD₅₀s in mice and rats, subacute oral toxicity in rats and dogs, and subacute topical ocular toxicity in rabbits have demonstrated the safety of this drug for human use.

Toxicology studies conducted with fluorometholone acetate are summarized in the following table:
<table>
<thead>
<tr>
<th>Test</th>
<th>Dosage (mg/kg)</th>
<th>Drug Related Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Toxicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse: i.p.</td>
<td>750, 1000, 1500, 2000</td>
<td>1890.7 (female); &gt;2000 (male)</td>
</tr>
<tr>
<td>Rat: i.p.</td>
<td>62.5, 125, 200, 500, 750, 1000</td>
<td>&gt; 1000</td>
</tr>
<tr>
<td>Rabbit: Ocular irritation</td>
<td>1.8 mg/eye over 6 hours</td>
<td>minimal-moderate conjunctival congestion, minimal conjunctival swelling and discharge</td>
</tr>
<tr>
<td>Long Term Toxicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse: 30 day</td>
<td>18 (p.o.)</td>
<td>Suppression of weight gain</td>
</tr>
<tr>
<td>Rat: 30 day</td>
<td>18 (p.o.)</td>
<td>Suppression of weight gain</td>
</tr>
<tr>
<td>Dog: 30 day</td>
<td>9 (p.o.)</td>
<td>Moderate fatty changes in liver</td>
</tr>
<tr>
<td>Dog: 5 day</td>
<td>3 (p.o.)</td>
<td>Increased glycogen deposition in liver; decreased adrenal weights</td>
</tr>
<tr>
<td>Rabbit: 5 day ocular irritation</td>
<td>0.5 mg/eye/day</td>
<td>Minimal conjunctival congestion</td>
</tr>
<tr>
<td>Rabbit: 45 day ocular irritation</td>
<td>0.5 mg/eye/day for 38 days</td>
<td>minimal-moderate conjunctival congestion; systemic steroid toxicity; 50% mortality rate at day 39</td>
</tr>
<tr>
<td>Rabbit: 30 day ocular irritation</td>
<td>0.8 mg/eye/day for 2 days; 0.5 mg/eye/day for 29 days</td>
<td>minimal-moderate conjunctival congestion; transient ocular discharge; transient diarrhea, loose stools and nasal discharge; suppression of weight gain</td>
</tr>
</tbody>
</table>

In reproduction studies, fluorometholone alcohol has been reported to be teratogenic and embryocidal when applied to both eyes of rabbits on days 6 to 18 of gestation, with dose-related fetal loss and fetal abnormalities including cleft palate, deformed rib cage, anomalous limbs and neural abnormalities such as encephalocele, craniorachischisis, and spina bifida. Cortisone, hydrocortisone and dexamethasone administered ocularly have also been reported to cause fetal anomalies in animal studies.

No studies have been conducted to evaluate the carcinogenicity or mutagenicity of fluorometholone.
BIBLIOGRAPHY


